CU23148A3 - Compuestos azapoliciclicos condensados con arilo - Google Patents

Compuestos azapoliciclicos condensados con arilo

Info

Publication number
CU23148A3
CU23148A3 CU177A CU20020177A CU23148A3 CU 23148 A3 CU23148 A3 CU 23148A3 CU 177 A CU177 A CU 177A CU 20020177 A CU20020177 A CU 20020177A CU 23148 A3 CU23148 A3 CU 23148A3
Authority
CU
Cuba
Prior art keywords
compounds
azapoliciclic
arilo
compounds condensed
formula
Prior art date
Application number
CU177A
Other languages
English (en)
Spanish (es)
Inventor
Paige Roanne Palmer Brooks
Jotham Wadsworth Coe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CU23148A3 publication Critical patent/CU23148A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
CU177A 2000-02-25 2002-08-21 Compuestos azapoliciclicos condensados con arilo CU23148A3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds

Publications (1)

Publication Number Publication Date
CU23148A3 true CU23148A3 (es) 2006-06-29

Family

ID=24045406

Family Applications (1)

Application Number Title Priority Date Filing Date
CU177A CU23148A3 (es) 2000-02-25 2002-08-21 Compuestos azapoliciclicos condensados con arilo

Country Status (40)

Country Link
US (3) US6605610B1 (US07205300-20070417-C00017.png)
EP (2) EP1259489B1 (US07205300-20070417-C00017.png)
JP (1) JP2003524002A (US07205300-20070417-C00017.png)
KR (1) KR100537976B1 (US07205300-20070417-C00017.png)
CN (1) CN1263745C (US07205300-20070417-C00017.png)
AP (1) AP1860A (US07205300-20070417-C00017.png)
AT (2) ATE328872T1 (US07205300-20070417-C00017.png)
AU (2) AU784081B2 (US07205300-20070417-C00017.png)
BG (1) BG65891B1 (US07205300-20070417-C00017.png)
BR (1) BR0108610A (US07205300-20070417-C00017.png)
CA (1) CA2401229C (US07205300-20070417-C00017.png)
CR (1) CR6726A (US07205300-20070417-C00017.png)
CU (1) CU23148A3 (US07205300-20070417-C00017.png)
CY (1) CY1105301T1 (US07205300-20070417-C00017.png)
CZ (1) CZ303203B6 (US07205300-20070417-C00017.png)
DE (2) DE60140965D1 (US07205300-20070417-C00017.png)
DK (2) DK1619192T3 (US07205300-20070417-C00017.png)
DZ (1) DZ3328A1 (US07205300-20070417-C00017.png)
EA (1) EA005316B1 (US07205300-20070417-C00017.png)
EE (1) EE200200475A (US07205300-20070417-C00017.png)
ES (2) ES2336800T3 (US07205300-20070417-C00017.png)
GE (1) GEP20053454B (US07205300-20070417-C00017.png)
HK (1) HK1050894A1 (US07205300-20070417-C00017.png)
HR (1) HRP20020700A2 (US07205300-20070417-C00017.png)
HU (1) HU229482B1 (US07205300-20070417-C00017.png)
IL (2) IL150639A0 (US07205300-20070417-C00017.png)
IS (1) IS2293B (US07205300-20070417-C00017.png)
MA (1) MA26875A1 (US07205300-20070417-C00017.png)
MX (1) MXPA02008311A (US07205300-20070417-C00017.png)
NO (1) NO323608B1 (US07205300-20070417-C00017.png)
NZ (1) NZ519973A (US07205300-20070417-C00017.png)
OA (1) OA12181A (US07205300-20070417-C00017.png)
PL (1) PL365163A1 (US07205300-20070417-C00017.png)
PT (1) PT1259489E (US07205300-20070417-C00017.png)
RS (1) RS51123B (US07205300-20070417-C00017.png)
SI (1) SI1259489T1 (US07205300-20070417-C00017.png)
SK (1) SK12042002A3 (US07205300-20070417-C00017.png)
UA (1) UA74813C2 (US07205300-20070417-C00017.png)
WO (1) WO2001062736A1 (US07205300-20070417-C00017.png)
ZA (1) ZA200206768B (US07205300-20070417-C00017.png)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1715280A (zh) * 1997-12-31 2006-01-04 辉瑞产品公司 芳基稠合氮杂多环化合物
DK1383733T3 (da) * 2001-04-20 2008-06-09 Pfizer Prod Inc Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser
EP1439836A1 (en) * 2001-10-31 2004-07-28 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
CA2468717A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Aryl fused azapolycyclic compounds
IL161857A0 (en) * 2001-11-30 2005-11-20 Pfizer Prod Inc Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene
EP2392345A3 (en) 2002-07-18 2012-03-07 Cytos Biotechnology AG Hapten-carrier conjugates comprising virus like particles and uses thereof
US7309458B2 (en) * 2002-10-22 2007-12-18 Millipore Corporation Multi-sided immersion formation of composite structures and method
KR100655848B1 (ko) * 2002-11-25 2006-12-11 화이자 프로덕츠 인크. 1,3-치환된 인덴의 개선된 제조 방법
MXPA05007565A (es) * 2003-01-15 2005-09-21 Pfizer Prod Inc Procedimiento mejorado de preparacion de lactamas policiclicas fusionadas con arilos.
EP1633358A1 (en) * 2003-05-20 2006-03-15 Pfizer Products Inc. Pharmaceutical compositions of varenicline
MXPA05013084A (es) * 2003-06-04 2006-03-02 Pfizer Prod Inc Preparacion de quinoxalinas sustituidas a partir de la dianilina con 2,3-dihidroxi-1,4-dioxano.
JP2006528170A (ja) * 2003-07-21 2006-12-14 ファイザー・プロダクツ・インク アリール縮合型アザ多環式化合物
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
SG147437A1 (en) 2003-10-14 2008-11-28 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
MXPA06007213A (es) * 2003-12-23 2006-08-18 Pfizer Prod Inc Combinacion terapeutica para la mejora de la cognicion y trastornos sicoticos.
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
BRPI0607838A2 (pt) * 2005-02-24 2009-06-13 Pfizer Prod Inc preparação de uma quinoxalina substituìda de pureza elevada
EP2012757A2 (en) * 2006-04-24 2009-01-14 Pfizer Products Incorporated Asymmetric membranes for drug delivery devices
BRPI0718600A2 (pt) * 2006-11-09 2013-12-10 Pfizer Prod Inc Polimorfos de intermediários nicotínicos.
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
BRPI0820668A2 (pt) * 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
JP5645217B2 (ja) * 2007-12-07 2014-12-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー ５，６−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用
US8703774B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
JP5701607B2 (ja) 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
JP2011516489A (ja) * 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
WO2009143347A2 (en) * 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
CA2752073A1 (en) * 2009-02-11 2010-08-19 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
EP2438054A1 (en) * 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
JP7137850B2 (ja) 2017-03-03 2022-09-15 シーティーシー バイオ インク バレニクリンまたはその薬学的に許容可能な塩の包接複合体を含む口腔投与用製剤
JP2023509453A (ja) * 2020-01-03 2023-03-08 ブルー オーク ファーマシューティカルズ インコーポレイテッド Ｃｎｓ障害を処置するための化合物および組成物
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CN1715280A (zh) * 1997-12-31 2006-01-04 辉瑞产品公司 芳基稠合氮杂多环化合物
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
DE69914594T2 (de) 1998-04-29 2004-12-09 Pfizer Products Inc., Groton Aryl-annellierte azapolycyclische verbindungen
CN1636996A (zh) * 1999-01-29 2005-07-13 艾博特公司 用作烟碱性乙酰胆碱受体配体的二氮杂二环衍生物
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
JP2004532826A (ja) * 2001-03-19 2004-10-28 スローン−ケッタリング インスティトゥート フォー カンサー リサーチ （ｓ，ｒ，ｒ）−（−）−アクチノニンおよびそのアナログの不斉合成、ならびにそれらの使用
JP2006528170A (ja) * 2003-07-21 2006-12-14 ファイザー・プロダクツ・インク アリール縮合型アザ多環式化合物
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Also Published As

Publication number Publication date
CA2401229C (en) 2007-10-02
UA74813C2 (en) 2006-02-15
BG106908A (bg) 2003-04-30
EP1619192B1 (en) 2009-12-30
CN1263745C (zh) 2006-07-12
OA12181A (en) 2006-05-09
EE200200475A (et) 2003-12-15
HK1050894A1 (en) 2003-07-11
KR100537976B1 (ko) 2005-12-21
AU2005234671B2 (en) 2008-04-17
NO20024042D0 (no) 2002-08-23
EA005316B1 (ru) 2004-12-30
RS51123B (sr) 2010-10-31
DK1619192T3 (da) 2010-03-29
DZ3328A1 (US07205300-20070417-C00017.png) 2001-08-30
PT1259489E (pt) 2006-08-31
GEP20053454B (en) 2005-02-25
IL150639A (en) 2011-10-31
HUP0204580A2 (hu) 2003-04-28
ES2263640T3 (es) 2006-12-16
BG65891B1 (bg) 2010-04-30
DK1259489T3 (da) 2006-10-09
AU2005234671A1 (en) 2005-12-15
YU59602A (sh) 2005-06-10
EP1619192A2 (en) 2006-01-25
CR6726A (es) 2003-10-28
DE60120366T2 (de) 2007-07-05
CY1105301T1 (el) 2010-03-03
IS2293B (is) 2007-10-15
CZ20022778A3 (cs) 2003-09-17
EP1259489B1 (en) 2006-06-07
CN1406227A (zh) 2003-03-26
ES2336800T3 (es) 2010-04-16
JP2003524002A (ja) 2003-08-12
EA200200716A1 (ru) 2003-02-27
DE60120366D1 (de) 2006-07-20
AU784081B2 (en) 2006-02-02
NO323608B1 (no) 2007-06-18
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
SK12042002A3 (sk) 2004-02-03
PL365163A1 (en) 2004-12-27
HU229482B1 (en) 2014-01-28
US20030130260A1 (en) 2003-07-10
KR20030005209A (ko) 2003-01-17
US6605610B1 (en) 2003-08-12
ATE453643T1 (de) 2010-01-15
BR0108610A (pt) 2002-11-19
ATE328872T1 (de) 2006-06-15
IL150639A0 (en) 2003-02-12
US20030130261A1 (en) 2003-07-10
EP1619192A3 (en) 2006-03-22
AP2002002604A0 (en) 2002-09-30
MXPA02008311A (es) 2002-12-09
SI1259489T1 (sl) 2006-10-31
HUP0204580A3 (en) 2005-04-28
IS6459A (is) 2002-07-05
DE60140965D1 (de) 2010-02-11
HRP20020700A2 (en) 2004-12-31
ZA200206768B (en) 2003-09-23
AU2874801A (en) 2001-09-03
CA2401229A1 (en) 2001-08-30
CZ303203B6 (cs) 2012-05-23
AP1860A (en) 2008-07-02
WO2001062736A1 (en) 2001-08-30
EP1259489A1 (en) 2002-11-27
US7144882B2 (en) 2006-12-05
US7205300B2 (en) 2007-04-17
MA26875A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
CU23148A3 (es) Compuestos azapoliciclicos condensados con arilo
UY27740A1 (es) Nuevos compuestos
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
CR9954A (es) Derivados de pirazina
PA8623001A1 (es) Compuestos de quinolina sustituidos
CR9834A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ECSP024399A (es) Derivados de benzotiazol
PA8551001A1 (es) Nuevos compuestos
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
HN2001000224A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
GT200000069A (es) Derivados heterociclicos utiles como agentes anticancerosos.
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
HN2008001666A (es) Derivados acidos de cicloalquilamino
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos
SV2006002135A (es) Nucleosidos de 3-beta-d-ribofuranosiltiazolo [4,5-d] pirimidina y usos de los mismos
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
PA8589801A1 (es) Aminoalcoxiindoles
PA8657701A1 (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
DOP2002000518A (es) Compuestos azapoliciclicos condensados con arilo
BRPI0412880A (pt) compostos azapolicìclicos fundidos a arila

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)